Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
1
17%
Ph phase_3
2
33%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

NCT05374564
terminatedphase_2

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

NCT02317783
completedphase_2

Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET

NCT01202994
completed

Implications for Management of PET Amyloid Classification Technology

NCT02778971
completedphase_3

Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images

NCT01672827
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05374564Phase 1

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Completed
NCT02317783Phase 2

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

Terminated
NCT01202994Phase 2

Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET

Completed
NCT02778971

Implications for Management of PET Amyloid Classification Technology

Completed
NCT01672827Phase 3

Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images

Completed
NCT01092546Phase 3

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6